Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic Fibrosis (RM/NEB-03-10)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2011 by Erempharma.
Recruitment status was  Recruiting
University of Lyon
Epidemiologie Pharmacologie Investigation Clinique Information medicale Mere Enfant (EPICIME)
Clininfo S.A.
Hospices Civils de Lyon
Information provided by:
Erempharma Identifier:
First received: April 13, 2011
Last updated: April 15, 2011
Last verified: February 2011
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)